Table 8.
Mutation status of BRAF and KRAS according to the promoter methylation status of hMLH1 and MGMT in serrated and non-serrated cancers
| hMLH1 methylation | MGMT methylation | |||||||
|---|---|---|---|---|---|---|---|---|
| Yes | No | All, N | Yes | No | ||||
| All, N | n (%) | n (%) | P-value | All, N | n (%) | n (%) | P-value | |
| Serrated adenocarcinoma | ||||||||
| BRAF V600E | 10 | 10 (100) | 0 (0.0) | 0.001 | 11 | 10 (90.9) | 1 (9.1) | 0.019 |
| Wild-type BRAF | 17 | 6 (35.3) | 11 (64.7 | 18 | 8 (44.4) | 10 (55.6) | ||
| KRAS c12/13 or c59/61 | 13 | 5 (38.5) | 8 (61.5) | 0.034 | 14 | 5 (35.5) | 9 (64.3) | 0.005 |
| Wild-type KRAS (all) | 14 | 11 (78.6) | 3 (21.4) | 15 | 13 (86.7) | 2 (13.3) | ||
| All non-serrated cancers | ||||||||
| BRAF V600E | 0 | 0 | 0 | NA | 0 | 0 | 0 | NA |
| Wild-type BRAF | 43 | 10 (23.3) | 33 (76.7) | 43 | 18 (41.9) | 25 (58.1) | ||
| KRAS c12/13 or c59/61 | 16 | 1 (6.3) | 15 (93.8) | 0.108 | 16 | 3 (18.8) | 13 (81.3) | 0.084 |
| Wild-type KRAS (all) | 25 | 7 (28.0) | 18 (72.0) | 25 | 13 (52.0) | 12 (48.0) | ||
| Matched non-serrated cancers | ||||||||
| BRAF V600E | 0 | 0 | 0 | NA | 0 | 0 | 0 | NA |
| Wild-type BRAF | 28 | 5 (17.9) | 23 (82.1) | 28 | 14 (25.0) | 14 (25.0) | ||
| KRAS c12/13 or c59/61 | 13 | 1 (7.7) | 12 (92.3) | 0.343 | 15 | 3 (23.1) | 10 (76.9) | 0.014 |
| Wild-type KRAS (all) | 16 | 4 (25.0) | 12 (75.0) | 16 | 11 (68.8) | 5 (31.2) | ||
NA, Not applicable.